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1. Gestational Diabetes Mellitus 
 
1.1. Definition, Prevalence and Diagnostic Criteria 
Diabetes mellitus is the most prevalent metabolic disorder affecting pregnant 
women [Negrato and Gomes, 2013]. Gestational diabetes mellitus (GDM) constitutes 
the most common type [Lappas et al., 2011], corresponding approximately to 90% of 
diabetic pregnancies, whereas type 1 (T1D) and type 2 diabetes account for the 
remaining 10% [Magon and Chauhan, 2012; Vargas et al., 2010]. 
GDM is defined as any degree of glucose intolerance with onset or first 
recognition during pregnancy (usually towards the late-second and early-third 
trimester) [ADA, 2013]. Its prevalence is difficult to compare from country to 
country due to the different diagnostic criteria used among distinct populations 
[Nolan, 2011]. In this sense, to promote the endorsement of consensual diagnostic 
criteria for GDM and, at the same time, to clarify the thresholds of maternal glycemia 
associated with an increased risk of adverse maternal, fetal and neonatal outcomes 
[Negrato and Gomes, 2013], the International Association of Diabetes in Pregnancy 
Study Group (IADPSG) Consensus Panel was created in 1998 [Metzger et al., 2010]. 
The results from the hyperglycemia and adverse pregnancy outcomes (HAPO) study 
[Metzger et al., 2008] along with other similar studies [Jensen et al., 2008; Pettitt et 
al., 1980; Sacks et al., 1995], served as the fundamental basis for the development of 
new diagnostic criteria by the IADPSG Consensus Panel. The HAPO study was a 
large-scale, multicentric and multiethnic epidemiologic research study which 
demonstrated for the first time that the risk of adverse perinatal outcomes, such as 
birth weight above the 90th percentile (large-for-gestational age [LGA] newborns), 
neonatal hyperinsulinemia, hyperbilirubinemia, hypoglycemia and adiposity, 
preterm delivery, cesarean section and preeclampsia, linearly increased as a 
function of maternal plasma glucose levels measured at 24-28 weeks of gestation. 
This association was present, even for glycemic ranges lower than that of overt 
diabetes [Metzger et al., 2008]. 
In 2010, the IADPSG Consensus Panel recommended that all women not 
previously diagnosed with diabetes before pregnancy should undergo a 75-g oral 
glucose tolerance test (OGTT) at 24-28 weeks of gestation. Attaining or exceeding 
any of the following plasma glucose thresholds would make a GDM diagnosis: 92 
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mg/dl (5.1 mM) for fasting plasma glucose, 180 mg/dl (10.0 mM) for 1-h OGTT 
plasma glucose or 153 mg/dl (8.5 mM) for 2-h OGTT plasma glucose [Metzger et al., 
2010]. These new diagnostic criteria, which were adopted by Portugal in 2011 
[Vicente and Boavida, 2011], significantly increased the prevalence of GDM to 
approximately 18% of all pregnancies (range 9.3-25.5%) [Sacks et al., 2012], which 
is more than the double of the prevalence based on older criteria [Homko, 2011], 
such as those of Carpenter and Coustan [Berggren et al., 2011].  This rise is 
explained by the fact that only one abnormal blood glucose value [Metzger et al., 
2010], in contrast to the older criteria that stipulated at least two (reviewed in 
[Negrato and Gomes, 2013]), is sufficient to make a GDM diagnosis [ADA, 2013].  
 
1.2. Etiology and Pathogenesis 
From the mid-second trimester until term, pregnancy is associated with a 
progressive increase in insulin resistance [Ben-Haroush et al., 2004] to ensure an 
appropriate glucose delivery to the growing fetus [Wong et al., 2002]. This appears 
to result from a combination of increased maternal adiposity and circulating levels 
of insulin-desensitizing hormones [Ben-Haroush et al., 2004; Buchanan and Xiang, 
2005], in particular human placental lactogen and growth hormone, progesterone, 
cortisol, prolactin and estrogen. Altered levels of adipose tissue-derived mediators, 
such as an increase in leptin and tumor necrosis factor-alpha (TNF-α) and a 
decrease in adiponectin have also been reported to contribute to pregnancy-induced 
insulin resistance [Golbidi and Laher, 2013; Vargas et al., 2010]. 
In normal pregnant women, this physiological insulin resistance is 
compensated by an increase in insulin secretion. However, in GDM women this 
compensatory insulin secretion is not sufficient to maintain response, and maternal 
hyperglycemia develops [Buchanan and Xiang, 2005]. So, hallmarks of GDM include 
insulin resistance, hyperglycemia [ADA, 2013; Ben-Haroush et al., 2004] and 
hyperinsulinemia [Lepercq et al., 1998]. Although not exclusive to GDM, 
hyperleptinemia [Ategbo et al., 2006; Guvener et al., 2012] and elevated levels of 
proinflammatory cytokines, such as TNF-α [Ategbo et al., 2006; Plomgaard et al., 
2007], are also associated with this disease. 
It is still poorly understood why the increase in insulin secretion is 
inadequate to accommodate the increased insulin resistance in GDM. Two of the best 
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characterized molecular mechanisms include: a) the presence of a defect in insulin 
post-receptor signaling pathway (phosphatidylinositol 3-kinase [PI3K]) in 
peripheral maternal tissues, thereby contributing to a reduced insulin-mediated 
glucose uptake [Friedman et al., 1999; Metzger et al., 2007], and b) a defect in 
pancreatic β-cell function [Metzger et al., 2007]. On the other hand, since GDM is a 
multifactorial disorder, several modifiable and non-modifiable factors may also 
explain the increased risk of developing this disease [Ben-Haroush et al., 2004]. 
These factors include: a) maternal overweight or obesity (pre-gravid body mass 
index ≥ 25) [Chu et al., 2007], b) advanced maternal age [Khalil et al., 2013], c) high 
parity (number of times a women has given birth) [Ben-Haroush et al., 2004], d) 
adverse obstetric outcomes in previous pregnancies (eg. stillbirth, LGA newborns 
and GDM) [Buchanan and Xiang, 2005] and e) diabetes in first-degree relative(s) 
[Buchanan and Xiang, 2005]. 
 
1.3. Perinatal and Long-term Outcomes 
As described in HAPO study (briefly reviewed in section 1.1.), GDM is 
associated with perinatal complications, in particular fetal macrosomia, which 
increases the risk of LGA newborn deliveries and traumatic birth injuries [Metzger 
et al., 2010; Metzger et al., 2008]. Furthermore, GDM increases the risk of the 
newborn to develop cardiovascular and metabolic diseases (obesity, type 2 diabetes 
and metabolic syndrome) [Boney et al., 2005; Gluckman et al., 2008; Lee et al., 2007] 
and neurological dysfunctions (inattention, hyperactivity and lower intelligence 
quotient scores) later in life [Ornoy, 2005; Stenninger et al., 1998]. Altogether, this 
data support the importance of GDM in fetal programming of adult diseases. 
Also, although most GDM women return to normal glucose tolerance after 
delivery [Kautzky-Willer et al., 2001], they present an increased risk of developing 
type 2 diabetes and having a cardiovascular event later in life [Metzger et al., 2007]. 
Maternal hyperglycemia is recognized as the main risk factor for the 
occurrence of adverse pregnancy outcomes associated with GDM [Biri et al., 2009; 
Pettitt et al., 2008; Simeoni and Barker, 2009; Yessoufou and Moutairou, 2011]. 
However, poor outcomes have also been reported in infants born from GDM 
mothers with an adequate glycemic control [Franks et al., 2006; Takayama-Hasumi 
et al., 1994], suggesting that, besides hyperglycemia, other GDM-associated 
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conditions, such as hyperinsulinemia, hyperleptinemia, inflammation and also 
oxidative stress - a condition in which cellular production of reactive oxygen species 
(ROS) overwhelms the ability of the antioxidant system to maintain ROS within 
physiological levels [Kohen and Nyska, 2002; Lappas et al., 2011] – may also be 
involved in GDM pathophysiology. In fact, oxidative stress could adversely affect 
insulin production by the pancreas leading to β-cell apoptosis, further exacerbating 
GDM metabolic phenotype [Herrera and Ortega-Senovilla, 2010]. 
The cellular and molecular mechanisms by which GDM and its conditions 
increase perinatal and later in life adverse health outcomes are still largely 
unexplored. However, some hypothesis have been raised, including changes in 
nutrient supply to the fetus, particularly fatty acids, amino acids and micronutrients 
[Metzger et al., 2007]; alterations in the expression of genes that control fetal growth 
and development by epigenetic mechanisms [Simeoni and Barker, 2009]; and 
alterations in placental development [Simeoni and Barker, 2009].  
Understanding how these mechanisms are altered in GDM will certainly 
contribute for a better understanding of GDM pathophysiology and to unveil 
pharmacological and nutritional strategies to prevent the occurrence of GDM 
complications. 
 
1.4. Management 
Antepartum care is absolutely essential to normalize maternal glycemia and 
to reduce the morbidity and mortality associated with GDM [Buchanan and Xiang, 
2005; Faraci et al., 2011]. Nutritional therapy is the first-line treatment [Metzger et 
al., 2007] but if adequate glycemic control is not achieved, subcutaneous insulin 
therapy is initiated. Physical exercise is also recommended for all GDM women 
capable of performing it [Golbidi and Laher, 2013]. 
Due to the similar effectiveness, but easier administration and lower cost 
when compared to insulin, selected oral anti-diabetic drugs (gliburyde and 
metformin) can be used as an alternative to insulin therapy [Relatório de Consenso 
sobre a Diabetes e Gravidez, 2011]. However, the risk/benefit of their use must be 
carefully assessed [Relatório de Consenso sobre a Diabetes e Gravidez, 2011], as 
their long-term safeness to the offspring health is still not completely proven [Nolan, 
2011]. 
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2. Human Placenta 
 
2.1. Structure and Functions 
In mammals, the placenta is the main interface between the maternal and 
fetal blood circulations [Fowden et al., 2008]. This transient organ of fetal origin 
performs multiple functions required for the growth and development of the fetus. 
Namely, a) it anchors the conceptus to the uterine wall and prevents its rejection by 
the maternal immune system [Fowden et al., 2008; Sandovici et al., 2012], b) it 
mediates the exchange of nutrients, respiratory gases, water and waste metabolites 
between maternal and fetal blood [Fowden et al., 2008] and c) it produces and 
metabolizes several hormones (including prolactin, progesterone, lactogen, growth 
hormone, chorionic gonadotropin and leptin), growth factors, cytokines and 
eicosanoids, that can be secreted into both the fetal and maternal circulations 
[Fowden et al., 2008; Fowden et al., 2009; Sandovici et al., 2012]. 
The human term placenta is constituted by three tissue layers: a) the 
syncytiotrophoblast (STB) epithelium, which is supported by an underlying 
basement membrane, b) the fetal connective tissue and c) the fetal capillary 
endothelium (Fig. 1) [Cleal and Lewis, 2008; Jansson et al., 2009]. 
During the first 21 days of pregnancy, trophoblast cells differentiate into 
villous or extravillous cytotrophoblasts. The extravillous cytotrophoblasts invade 
the myometrium and uterine vasculature, being essential for the anchorage of the 
placenta to the uterus, whereas villous cytotrophoblasts differentiate and fuse 
originating the STB layer [Malassine et al., 2003]. This layer has two polarized 
plasma membranes: the microvillous membrane (MVM), directed towards the 
maternal blood, and the basal membrane (BM), facing fetal capillaries [Jansson et al., 
2009] (Fig. 1). Since maternal blood comes into direct contact with the STB the 
human placenta is designated as hemochorial [Carter, 2012]. This placental type is 
also typical of many rodents and primates.  
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Fig. 1. Representation of the human term placenta structure at the maternal-to fetal interface. 
 
The STB epithelium is the most important placental tissue actively involved 
in the maternal-to-fetal transport of nutrients such as glucose, amino acids, fatty 
acids, vitamins and ions [Desforges and Sibley, 2010; Jansson et al., 2009; Sandovici 
et al., 2012]. Nutrient transport across the STB can occur by simple diffusion, 
protein-mediated transport or by receptor-mediated endocytosis [Desforges and 
Sibley, 2010]. The rate at which these processes occur depend mainly on the 
physico-chemical characteristics of the nutrient (eg. electrical charge and 
hydrophilicity/hydrophobicity) [Desforges and Sibley, 2010], but are also 
dependent on placental size, surface area, thickness and metabolism (ie. nutrient 
consumption and production) [Fowden et al., 2008; Lager and Powell, 2012], 
nutrient concentration gradient between maternal and fetal circulations [Fowden et 
al., 2009], and on uteroplacental and fetal vasculature and blood flow. Moreover, 
placental transport also depends upon the location, expression and activity of 
transporter proteins present in the STB plasma membranes [Fowden et al., 2008; 
Lager and Powell, 2012]. 
In vivo, transport across the human placenta can be studied by measuring the 
appearance of nutrients labeled with stable isotopes (eg. 13C) in cord blood, after 
their administration to the mother [Haggarty, 2010]. However, since these studies 
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give us an indirect measure of transport (as it is inferred from isotope concentration 
differences between the maternal and fetal blood circulations), in vitro placental 
models have been developed in order to directly access transport rates [Haggarty, 
2010], namely placental explants, STB membrane vesicles and cell cultures of human 
trophoblasts (primary cells and cell lines) [Levkovitz et al., 2013]. 
 
2.2. Placental Transport of Nutrients 
The transplacental transport of nutrients is of particular importance to 
assure an adequate fetal growth and development [Avagliano et al., 2012]. 
Moreover, changes in nutrient transport capacity across the STB membranes have 
been associated with abnormal size and weight at birth, which, as first noted by 
[Barker et al., 1993], are both major determinants of perinatal morbidity and 
mortality and of later in life development of cardiovascular and metabolic diseases 
[Jansson et al., 2009; Lager and Powell, 2012].  
The major subject of this study was to investigate the impact of GDM upon 
placental transport of the nutrients folic acid (FA), L-methionine (L-Met), 
arachidonic (AA) and docohexaenoic (DHA) acids and glucose. So, in the next section 
we will briefly describe the main principles of FA, amino acids, long-chain 
polyunsaturated fatty acids (LC-PUFAs) and glucose placental transport. 
 
2.2.1. FA Transporters 
 FA or pteroylmonoglutamate is the parent structure and oxidized form of the 
B9 family of water-soluble vitamins known as folates [Lucock, 2000]. N5-
methyltetrahydrofolate, a reduced folate, is the most common form naturally 
occuring in food [Lucock, 2000], and nutritional supplements and fortified foods are 
the most abundant dietary sources of FA [Caballero et al., 2005; Lucock, 2000].  
 Folates are  essential micronutrients that facilitate the intracellular transfer 
of one-carbon units required for a) the synthesis of purine and pyrimidine 
precursors of nucleic acids [Lucock, 2000], b) the occurrence of methylation 
reactions [Farkas et al., 2013], c) the initiation of protein synthesis in the 
mitochondria and d) the metabolism of some amino acids (L-Met, L-Serine [L-Ser], 
Glycine and L-Histidine) [Lucock, 2000] (Fig. 2). Due to this, folates play a crucial 
role in the process of cell division and proliferation, being thus particularly 
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important during pregnancy to assure placental and fetal development and uterine 
expansion [Caballero et al., 2005; Lucock, 2000]. 
 
Purines
5-MTHF
THF
5,10-MTHF
Pyrimidines
Serine
Glycine
MS
(vit. B12)
Methionine
BHMT
DMG
Betaine
Homocysteine
SAM
SAH
Methyl acceptor
Methylated 
product
Methyltransferase
DNA, Histones
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Fig. 2. Interaction of folic acid, methionine and docosahexaenoic acid in one carbon cycle.  
5,10-MTHF: N5,N10-methylenetetrahydrofolate; 5-MTHF: N5-methyltetrahydrofolate; BHMT: betaine–
homocysteine methyltransferase; DHA: docosahexaenoic acid; DMG: dimethylglycine; MS: methionine 
synthase; SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; THF: tetrahydrofolate; vit B12: 
vitamin B12. 
 
 The increased demand for folates during pregnancy is well demonstrated by 
the fact that maternal folate deficiency, the most common vitamin deficiency in 
developed countries [Caballero et al., 2005], is associated with an increased risk of 
low birth weight, spontaneous abortion, and neural tube defects (NTDs) (eg. spina 
bifida and anencephaly) [Caballero et al., 2005; Lucock, 2000; Zhao et al., 2011]. 
Moreover, FA supplementation during the periconceptional period reduces the 
incidence of such outcomes, particularly of NTDs [Caballero et al., 2005; CDC, 1991; 
Lucock, 2000].  
 Neither the placenta nor the fetus is able to synthesize folates, so this vitamin 
must be obtained from the maternal circulation through placental transport 
[Giugliani et al., 1985; Hutson et al., 2012]. The human placenta expresses three 
specific folate transporters, namely the reduced folate carrier (RFC1), the alpha 
isoform of the folate receptor (FR) and the proton-coupled folate transporter 
(PCFT). All of them act coordinately to ensure the vectorial transfer of folates from 
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maternal to fetal circulation [Keating et al., 2009a; Solanky et al., 2010; Zhao et al., 
2009] (Fig. 3).  
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Fig. 3. Main folic acid transporters present at the human syncytiotrophoblast. 
      : folic acid; BM: basal membrane; CTB: cytotrophoblast; FR: folate receptor alpha; FE: fetal 
endothelium; MVM: microvillous membrane; N: nucleus; OP+: organic phosphates; PCFT: proton-
coupled folate transporter; STB: syncytiotrophoblast; RFC1: reduced folate carrier. 
 
 RFC1 is a folate:organic phosphate exchanger that utilizes the 
transmembrane organic phosphate gradient to mediate the uphill transport of 
folates into cells [Zhao et al., 2011; Zhao et al., 2009]. This bidirectional transporter 
is expressed in both MVM and BM of the STB [Solanky et al., 2010] (Fig. 3), has a 
maximal activity at physiological pH, and a higher affinity for reduced folates (such 
as N5-methyltetrahydrofolate) over non-reduced folates [Zhao et al., 2011; Zhao et 
al., 2009]. FRα is a high-affinity folate-binding protein selectively expressed in the 
MVM of the STB (Fig. 3). This transporter is embedded in the membrane by a 
glycosylphosphoinositol anchor [Solanky et al., 2010; Zhao et al., 2011; Zhao et al., 
2009] and mediates the unidirectional uptake of folates at neutral to mildly acidic 
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pH. FRα has a higher affinity for non-reduced over reduced folates [Zhao et al., 2011; 
Zhao et al., 2009]. Concerning PCFT, this transporter is a high affinity folate:H+ 
symporter, with an optimal activity at acidic pH (5.5–6.0), that utilizes the 
transmembrane H+ gradient to achieve the uphill transport of folates into cells 
[Keating et al., 2009a; Zhao et al., 2011; Zhao et al., 2009]. PCFT is predominantly 
present at the MVM, where it co-localizes with FRα [Solanky et al., 2010] (Fig. 3). 
 Recently, Solanky and co-workers proposed a model for folates transport 
across the human STB (Fig. 3). The initial step involves binding of folates to FRα 
localized in the MVM. Co-localization of this transporter with PCFT allows the 
internalization of both into an endosome. During cytoplasmic transit, this endosome 
is acidified (pH 6.0–6.5) due to an influx of protons, which promotes the dissociation 
of folates from FRα and establishes a favourable H+ gradient that allows PCFT-
mediated folate efflux into the cytoplasm. FRα and PCFT are then re-cycled back to 
the MVM surface. At the MVM, RFC1 provides an alternative pathway for folates 
uptake. Efflux across the BM does not involve neither FRα nor PCFT but instead 
RFC1. 
Other potential folate transporters localized at BM and MVM of the STB 
(namely the ATP-binding cassette efflux transporters: multidrug resistance-
associated proteins and breast cancer resistance protein [Zhao et al., 2011]), may 
also play a role in FA transport but their exact contribution is still poorly 
understood. 
 
2.2.1.1. Regulation of placental FA transport  
Despite the recognized importance of folates for fetal development, 
knowledge on the cellular mechanisms involved in its transfer across the placenta is 
still very limited. Available data indicates that placental uptake of FA is 
downregulated by chronic hyperglycemia, some anti-hypertensive drugs, drugs of 
abuse and ethanol [Keating et al., 2009a], and is differently modulated by 
polyphenolic compounds and methylxanthines [Keating et al., 2008]. Although 
maternal folates deficiency and low birth weight are intimately associated, a 
decrease in folates placental transport has not been demonstrated in FGR [Bisseling 
et al., 2004]. Instead, an increase was reported by Keating and co-workers, which 
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suggested that the placenta exhibited “a compensation for the weakness effect" 
[Keating et al., 2009b]. 
 
2.2.2. Amino acid Transporters 
Besides being used as building blocks for fetal protein synthesis, amino acids 
constitute important energy substrates for both the fetus and the placenta [Jansson 
et al., 2009] and they are biosynthetic precursors of purines, pyrimidines, 
neurotransmitters, nitric oxide, glutathione, polyamines and haem [Cleal and Lewis, 
2008; Grillo et al., 2008]. By virtue of not being synthesized by the fetus or placenta, 
placental transport of nutritionally essential amino acids from the maternal 
circulation is determinant for these functions to occur. 
L-Met is a nutritionally essential large neutral amino acid that plays a key role 
in one-carbon metabolism. After conversion to S-adenosylmethionine, this amino 
acid provides the methyl groups necessary for the methylation of DNA, RNA, 
proteins, biogenic amines and phospholipids (Fig. 2). The importance of L-Met 
during pregnancy is well demonstrated by the higher occurrence of NTDs in women 
with low dietary intake of L-Met, and FGR in animal models of L-Met intake 
restriction during pregnancy [Kalhan and Marczewski, 2012]. 
Epigenetic regulation, in particular DNA methylation, plays a crucial role in 
gene expression, imprinting processes and embryonic development, thereby 
programming the fetus for future development of diseases [Jansson and Powell, 
2007]. Since biological methylation reactions depend on the availability of L-Met 
[Mato et al., 2008], and also of FA, changes in the placental transport of these 
methyl-related nutrients will alter their availability to the fetus, providing a direct 
link between placental function, gene methylation and fetal programming [Jansson 
and Powell, 2007]. 
The concentration of most amino acids, including L-Met, at the placental level 
is normally higher than that found in both fetal and maternal circulation [Cleal and 
Lewis, 2008]. This suggests that their uptake across the MVM into the STB occurs 
mainly by active processes [Desforges and Sibley, 2010], whereas their transport 
across the BM into the fetal blood is mainly passive [Burton et al., 2011].  
Based on the functional characteristics of amino acid transport systems, such 
as substrate specificity, inhibition by L-Met and placental location, four different 
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transporters have been identified in the human STB as capable of transporting L-
Met: systems A, L, y+L and b0+ [Cleal and Lewis, 2008; Kudo and Boyd, 1990; Tsitsiou 
et al., 2009] (Fig. 4). 
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Fig. 4. Main L-methionine transport systems present at the human syncytiotrophoblast.  
     : amino acids; BM: basal membrane; CTB: cytotrophoblast; FE: fetal endothelium; LAT: L-type 
amino acid transporter; MVM: microvillous membrane; N: nucleus; SNAT: sodium coupled neutral 
amino acids transporter; STB: syncytiotrophoblast; ?: expression not confirmed. 
 
The Na+-dependent system A transporters mediate the uptake of neutral 
amino acids (both essential and non essential) with short and unbranched side 
chains, mostly L-Alanine (L-Ala), Glycine, L-Ser, L-Met and L-Glutamine [Cleal and 
Lewis, 2008; Desforges and Sibley, 2010]. Although system A activity is present in 
both MVM and BM of the STB, its activity is highly polarized to the MVM [Jansson et 
al., 2001]. In agreement with this, the system A isoforms sodium-coupled neutral 
amino acids transporter 1 (SNAT1), SNAT2 and SNAT4 are expressed mainly in the 
MVM in comparison with the BM [Burton et al., 2011] (Fig. 4). SNAT1-4 are 
accumulative transporters that mediate the influx of amino acids from maternal 
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circulation into the STB, creating an outwardly directed concentration gradient that 
will enable them to be transported outside the STB, towards the fetal circulation, by 
using other amino acid transport systems. 
System L is a Na+-independent amino acid transport system and the main 
route for the transport of many neutral (eg. L-Met), branched-chain (eg. L-Leucine) 
and aromatic (eg. L-Phenylalanine and L-Tyrosine) amino acids [Burton et al., 2011; 
Cleal and Lewis, 2008]. Cellular localization of system L isoforms is polarized, with 
L-type amino acid transporter 1 (LAT1) and LAT2 being primarily, although not 
exclusively, expressed in the MVM and BM, respectively (Fig. 4). Both of them allow 
the exchange of intracellular non-essential amino acids (eg. transported by system 
A) for extracellular essential amino acids, driving the uptake into STB of essential 
amino acids [Burton et al., 2011]. Additionally, LAT3 and LAT4 system L isoforms, 
which are expressed in the BM of the STB, act as efflux transporters of amino acids 
from the STB to the fetal circulation [Lager and Powell, 2012] (Fig. 4).  
Besides the neutral amino acids transport systems mentioned above 
(systems A and L), placental transport of L-Met also appears to involve the cationic 
amino acid transport systems y+L and bo,+. 
System y+L (represented by y+LAT1 and y+LAT2 amino acid transporters) 
have been described to be present in both MVM and BM of the human STB (Fig. 4); 
however, it is much more abundant at the BM. This system has been described to 
exchange cationic amino acids (eg. L-Lysine, L-Lys), which are transported out of the 
STB down their electrical potential gradient, for neutral amino acids (eg. L-Leucine, 
L-Met) plus Na+, which are transported into the STB [Grillo et al., 2008]. System bo,+ 
(isoform b0,+AT) has similar characteristics as y+L, except that it transports neutral 
amino acids in the absence of Na+ [Battaglia and Regnault, 2001; Cleal and Lewis, 
2008; Jansson, 2001]. More detailed information about system bo,+ activity and 
expression in the STB membranes is at the moment scarce and conflicting [Ayuk et 
al., 2000; Jansson, 2001] (Fig. 4). 
 
2.2.2.1. Regulation of placental amino acids transport  
In placentas obtained from FGR newborns, the activity and expression of 
systems A, L and y+L, and of cationic amino acid transporter system y+ and aromatic 
amino acid transporter system T were shown to be reduced in MVM and/or BM of 
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the STB (reviewed by [Avagliano et al., 2012; Larque et al., 2013]). On the other 
hand, in fetal overgrowth [Jansson et al., 2013; Jansson et al., 2002] the activity and 
expression of system A transporters appears to be increased in MVM. Collectively, 
these data show that reduced fetal growth is associated with a downregulation 
whereas fetal overgrowth appears to be associated with an upregulation of placental 
amino acid transporters. Whether these alterations are a cause or a consequence of 
impaired fetal growth, is at the moment difficult to address [Cleal and Lewis, 2008]. 
The placental transport of amino acids is regulated by several maternal and 
fetal factors [Cleal and Lewis, 2008]. Hormones (insulin and leptin) growth factors 
(insulin-like growth factors) [Cleal and Lewis, 2008; Fowden et al., 2009], 
proinflammatory cytokines (interleukin (IL)-6 and TNF-α) and glucocorticoids 
(cortisol) [Burton et al., 2011; Fowden et al., 2009] have been shown to increase 
system A transporter activity and SNAT1 and 2 expression. Conversely, adiponectin, 
IL-1β, angiotensin II, hypoxia and oxidative stress reduce system A activity and/or 
SNAT2 expression (reviewed by [Burton et al., 2011; Lager and Powell, 2012]).  
System L is only affected by adiponectin, which downregulates its activity 
[Rosario et al., 2012] and by insulin, which either increases or does not affect its 
activity (Lager and Powell, 2012). The intracellular signaling pathway mammalian 
target of rapamycin (mTOR) acts as a positive regulator of both systems A and L 
[Jansson et al., 2012; Rosario et al., 2013]. 
 
2.2.3. LC-PUFAs Transporters 
The nutritionally essential LC-PUFAs AA (20:4n-6) and DHA (22:6n-3) play a 
fundamental role for both the health of the pregnant woman and for the growth and 
development of the fetus [Innis, 1991]. Apart from serving as an energy substrate, 
LC-PUFAs are essential components of cellular membranes, maintaining their 
structure and function, and act as regulators of gene expression via nuclear 
receptors [Schmitz and Ecker, 2008] and DNA methylation [Kulkarni et al., 2011] 
(Fig. 2).  
AA is essential for the synthesis of eicosanoids such as prostaglandins and 
leukotrienes, which are important for the development of fetal nervous, visual, 
immune and vascular systems [Cunningham and McDermott, 2009; Duttaroy, 2009] 
and for labour [Allen and Harris, 2001]. DHA is also essential for the development of 
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the fetal neurovisual system, being incorporated in high concentrations in the brain 
and retina [Cunningham and McDermott, 2009; Duttaroy, 2009]. Through the 
conversion of phosphatidylethanolamine-DHA to phosphatidylcholine-DHA, DHA 
levels were shown to regulate methyl group availability [Kulkarni et al., 2011] (Fig. 
2). A depletion of both AA and DHA in fetal tissues is associated with cognitive, 
behavioral and visual abnormalities later in life [Innis, 2005]. Accordingly, several 
studies suggest that maternal LC-PUFAs supplementation during pregnancy 
improves neurodevelopmental functions of the infants (reviewed in [Larque et al., 
2011; Ryan et al., 2010]) and, at the same time, reduces the risk of preterm delivery 
[Greenberg et al., 2008] and low birth weight [Carlson et al., 2013; Greenberg et al., 
2008; Larque et al., 2012]. Based on this, the European Food Safety Authority (EFSA) 
recommends that maternal intake of LC-PUFAs should be increased during 
pregnancy and lactation [EFSA, 2010].  
Optimal fetal growth and development depends on an adequate supply of AA 
and DHA from maternal circulation [Duttaroy, 2009; Haggarty, 2010; Johnsen et al., 
2009]. Interestingly, most LC-PUFAs are present at higher concentrations in fetal 
than in maternal circulation [Hanebutt et al., 2008] - a phenomenon termed 
biomagnification [Larque et al., 2011]. This is thought to be the result of a selective 
and more efficient placental transport of LC-PUFAs, over non-essential shorter fatty 
acids, in favor of the fetus [Haggarty, 2010]. 
LC-PUFAs transported across the human STB are mainly derived from 
triglyceride-rich lipoproteins (from which they must be released by the action of 
placental lipases) and from fatty acids bound to albumin [Hanebutt et al., 2008] (Fig. 
5). Although LC-PUFAs may be taken up by the STB via passive diffusion, membrane-
associated fatty acid transport proteins are also implicated in this transport process. 
Namely, placental plasma membrane fatty acid binding protein (pFABPpm), fatty 
acid transport proteins (FATP) and fatty acid translocase (FAT/CD36) [Duttaroy, 
2009; Haggarty, 2010]. Additionally, intracellular fatty acid binding proteins (FABP), 
in particular FABP 1, 3 and 4, are responsible for directing fatty acids to their 
specific intracellular locations [Cunningham and McDermott, 2009; Duttaroy, 2009] 
(Fig. 5). The precise mechanisms by which these transport proteins facilitate 
transmembrane passage of LC-PUFAs are still a matter of speculation. 
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Fig. 5. Long-chain polyunsaturated fatty acids transport at the human syncytiotrophoblast. 
         : long-chain polyunsaturated fatty acid; ACSL: long-chain acyl-CoA synthetases; BM: basal 
membrane; CTB: cytotrophoblast; FATP: fatty acid transport proteins; FAT/CD36: fatty acid 
translocase; EL: endothelial lipase; FE: fetal endothelium; LP: lipoprotein; LPL: lipoprotein lipase; 
LPr: lipoprotein receptor; MVM: microvillous membrane; N: nucleus; pFABPpm: placental plasma 
membrane fatty acid binding protein; STB: syncytiotrophoblast. 
 
pFABPpm is an unidirectional placenta-specific transporter with preferential 
affinity for DHA and AA, that is found exclusively on the MVM of term STB (Fig. 5) 
[Cunningham and McDermott, 2009; Duttaroy, 2009]. 
The FATP family (FATP1–6) transports fatty acids in an ATP-dependent 
manner with no preference for any particular LC-PUFA [Duttaroy, 2009; Richards et 
al., 2003], and FATP1, 2 and 4 are expressed in the MVM and BM of the human STB 
[Cunningham and McDermott, 2009] (Fig. 5). A still ongoing debate about FATP is 
whether they act solely as transmembrane transport proteins or if they also harbor 
long-chain acyl-CoA synthetase (ACSL) activity [Bonen et al., 2007; Duttaroy, 2009]. 
ACSL are a group of cytosolic enzymes that trap and prevent the efflux of 
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intracellular fatty acids by converting them into acyl-CoA derivatives for further 
esterification or β-oxidation [Pohl et al., 2004; Weedon-Fekjaer et al., 2010]. These 
enzymes, in particular ACSL1, 3, 4, 5 and 6, have been proven to be involved in LC-
PUFAs uptake by trophoblasts [Duttaroy, 2009; Haggarty, 2010; Johnsen et al., 
2009]. 
FAT/CD36 is a glycoprotein receptor that allows bididirectional and non-
selective transport of fatty acids, being expressed in both membranes of the STB 
(Fig. 5) [Haggarty, 2010]. At the present, it still arguable if FAT/CD36 is really 
important for AA and DHA placental transport [Cunningham and McDermott, 2009]. 
 
2.2.3.1. Regulation of placental transport of LC-PUFAs 
Alterations in placental LC-PUFAs transport may occur in pregnancies 
complicated by FGR, obesity or diabetes. Fetal:maternal blood ratio of AA and DHA 
was found to be lower in FGR pregnancies compared with normal pregnancies 
[Hanebutt et al., 2008]. Despite FAT/CD36 [Laivuori et al., 2006] and FABP1 and 3 
[Cunningham and McDermott, 2009] gene expression being unchanged in placentas 
from growth restricted fetuses, the activity of lipoprotein lipase  was found to be 
decreased, thereby reducing the availability of free fatty acids to be transported by 
the STB [Magnusson et al., 2004b]. 
Recently, Dube et al. suggested that maternal obesity differently modulates 
placental LC-PUFAs uptake: a decrease in FATP4 expression and trophoblast linoleic 
acid transport but, at the same time, an increase in CD36 expression [Dube et al., 
2012]. 
An upregulation in the expression levels of FABP1, 3 and 4 [Magnusson et al., 
2004b; Radaelli et al., 2009] and ACSL2, 3 and 4 [Radaelli et al., 2009] have been 
described in GDM and T1D placentas, suggesting an increase in LC-PUFAs placental 
accumulation [Gauster et al., 2011; Magnusson et al., 2004b]. On the other hand, 
plasma levels of AA and DHA in neonates born from T1D, type 2 diabetes and GDM 
women (reviewed by [Herrera and Ortega-Senovilla, 2010]) was lower than those 
born from control woman. This apparently inconsistent data suggests that placental 
LC-PUFAs transport in diabetic pregnancies may be impaired [Herrera and Ortega-
Senovilla, 2010]. So, transport capacity at the STB level needs to be assessed in 
diabetic pregnancies to better understand this point. 
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2.2.4. Glucose Transporters 
Glucose is the principal energy substrate for the feto-placental unit and, together 
with amino acids, constitutes the primary stimuli for fetal secretion of the growth-
promoting hormone insulin [Jansson et al., 2009]. 
Placental transport of glucose occurs mainly through facilitative glucose 
transporters (GLUT) [Day et al., 2013]. At least four different GLUT isoforms are 
expressed in the human STB: GLUT1, 3, 4 and 12. However, the primary isoform 
responsible for glucose transport across both membranes of the STB is believed to 
be GLUT1 [Baumann et al., 2002; Carter, 2012; Jansson et al., 2009] (Fig. 6). GLUT1 
distribution in the STB is asymmetric, with a greater expression and activity in the 
MVM, which assures that glucose is transported down its concentration gradient 
from maternal to fetal circulation [Baumann et al., 2002; Carter, 2012]. This led to 
the proposal that GLUT-mediated transport across the BM of the STB constitutes the 
rate limiting step in placental glucose transfer [Lager and Powell, 2012] (Fig. 6). 
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Fig. 6. Glucose transport at the human syncytiotrophoblast. 
: glucose; BM: basal membrane; CTB: cytotrophoblast; FE: fetal endothelium; GLUT1: facilitative 
glucose transporter isoform 1; MVM: microvillous membrane; N: nucleus; STB: syncytiotrophoblast. 
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Glucose transporters other than GLUT1, namely GLUT3 and the insulin-sensitive 
GLUT4 and 12, are found in first trimester STB, and play an important role earlier in 
gestation [Baumann et al., 2002; Brown et al., 2011; Lager and Powell, 2012]. In 
accordance with this, insulin was shown to stimulate glucose transport in first 
trimester but not in term placentas [Challier et al., 1986; Ericsson et al., 2005]. 
However, this point is still not completely clarified [Baumann et al., 2002]. 
 
2.2.4.1. Regulation of placental glucose transport 
Alterations in placental glucose transport and metabolism have been reported to 
occur in pregnancy disorders associated with aberrant fetal growth [Baumann et al., 
2002; Desoye et al., 2011; Illsley, 2000; Magnusson et al., 2004a]. 
In T1D and GDM women, GLUT1 expression and activity was shown to be 
increased in the BM of the STB [Baumann et al., 2002; Gaither et al., 1999] whereas 
in growth restricted fetuses, GLUT1 expression and activity were unaltered 
[Baumann et al., 2002] but placental glucose metabolism was decreased [Magnusson 
et al., 2004a]. 
Some metabolic conditions have also been reported to regulate placental glucose 
transport in human trophoblasts [Baumann et al., 2002]. An inverse relationship 
was demonstrated between extracellular glucose concentration and GLUT1 
expression and activity [Hahn et al., 1998; Illsley et al., 1998], suggesting a 
downregulation in GLUT1 in response to excess glucose. Additionally, 
corticotrophin-releasing hormone [Gao et al., 2012], insulin-like growth factor-1, 
growth hormone and hypoxia (reviewed by [Baumann et al., 2002]) upregulated,  
whereas glucocorticoids downregulated [Fowden et al., 2009] GLUT1 expression.   
 
2.3 The Placenta as a nutrient sensor 
The placenta has been proposed to acts as a nutrient sensor, by regulating the 
transport capacity of nutrients in response to maternal or fetal stimuli [Jansson and 
Powell, 2013]. According to this model, in the presence of a ‘low nutritional 
environment’, like maternal under-nutrition (which induces FGR), the fetus signals 
the placenta to upregulate nutrients transport (eg. folic acid, see section 2.2.1.1.) 
through nutrient sensing signaling pathways, such as mTOR. However, this is 
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inconsistent with data showing that placental transport of amino acids is 
downregulated in FGR (see section 2.2.2.1.) [Jansson and Powell, 2013]. As a whole, 
these obervations show that the nutrient sensing function of the placenta is still not 
completely understood being presently an attractive area of research [Jansson and 
Powell, 2013]. 
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The main aim of this study was to investigate the impact of GDM and its 
associated hallmarks upon placental nutrient transport and development. 
To accomplish this, the specific aims of this study were: 
 
CHAPTER I - Characterization of placental nutrient transport and 
placental development in normal and GDM pregnancies 
 
 to characterize and to compare the uptake of 3H-FA, 14C-L-Met, 14C-AA 
and 14C-DHA by primary cultured human cytotrophoblasts obtained 
from normal (NTB cells) and GDM pregnancies (DTB cells) 
 
 to compare the viability, proliferation, differentiation and apoptosis of 
NTB and DTB cells 
 
CHAPTER II – Assessment of a GDM-associated hallmark (oxidative 
stress) at placental level 
 
 to assess oxidative stress status in GDM placentas 
 
CHAPTER III – Modulation of placental nutrient transport by GDM-
associated hallmarks 
 
 to study the effect of oxidative stress upon the uptake of 3H-
deoxyglucose (3H-DG) by the BeWo choriocarcinoma cell line 
 
 to investigate the effect of hyperglycemia, hyperinsulinemia, 
hyperleptinemia, and increased levels of inflammation and oxidative 
stress upon the transport of FA, neutral amino acids and LC-PUFAs in 
BeWo or NTB cells  
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Characterization of placental nutrient transport and placental development 
in normal and GDM pregnancies 
 
The information contained in this chapter is included in the following original 
publications: 
 
A. Araújo JR, Correia-Branco A, Moreira L, Ramalho C, Martel F, Keating E. Folic acid uptake by 
the human syncytiotrophoblast is affected by gestational diabetes, hyperleptinemia, and 
TNF-α.  
 
Pediatr Res. 2013;73:388-394 
DOI: 10.1038/pr.2013.14. 
IF: 2.67 
 
B. Araújo JR, Correia-Branco A, Ramalho C, Gonçalves P, Pinho MJ, Keating E, Martel F. L-
methionine placental uptake: characterization and modulation in gestational diabetes 
mellitus.  
 
Reprod Sci. 2013;20:1492-1507 
DOI: 10.1177/1933719113488442 
IF: 2.06 
 
C. Araújo JR, Correia-Branco A, Ramalho C, Keating E, Martel F. Gestational diabetes mellitus 
decreases placental uptake of long-chain polyunsaturated fatty acids: involvement of long-
chain acyl-CoA synthetase.  
 
J Nutr Biochem. 2013;24:1741-1750 
DOI: 10.1016/j.jnutbio.2013.03.003. 
IF: 4.55 
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Assessment of a GDM-associated hallmark (oxidative stress) at placental level 
 
The information contained in this chapter is included in the following original 
publication: 
 
D. Araújo JR, Ramalho C, Correia-Branco A, Faria A, Ferraz T, Keating E, Martel F. Parallel 
increase in placental oxidative stress and antioxidant defenses occurs in type 1 but not 
gestational diabetes.  
 
Placenta. 2013;34:1095-1098. 
DOI: 10.1016/j.placenta.2013.09.001. 
IF: 3.12  
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Modulation of placental nutrient transport by GDM-associated hallmarks 
 
The information contained in this chapter is included in the following original 
publications: 
 
E. Araújo JR, Gonçalves P, Martel F. Modulation of glucose uptake in a human choriocarcinoma 
cell line (BeWo) by dietary bioactive compounds and drugs of abuse.  
 
J Biochem. 2008;144:177-186  
DOI: 10.1093/jb/mvn054. 
IF: 2.72 
 
F. Araújo JR, Pereira AC, Correia-Branco A, Keating E, Martel F. Oxidative stress induced by tert-
butylhydroperoxide interferes with the placental transport of glucose: in vitro studies with 
BeWo cells. 
 
Eur J Pharmacol. In press 
DOI: 10.1016/j.ejphar.2013.10.023. 
IF: 2.59 
 
G. Araújo JR, Correia-Branco A, Pereira AC, Pinho MJ, Keating E, Martel F. Oxidative stress 
decreases uptake of neutral amino acids in a human placental cell line (BeWo cells).  
 
Reprod Toxicol. 2013;40:76-81 
DOI: 10.1016/j.reprotox.2013.06.073. 
IF: 3.14 
 
A. Araújo JR, Correia-Branco A, Moreira L, Ramalho C, Martel F, Keating E. Folic acid uptake by 
the human syncytiotrophoblast is affected by gestational diabetes, hyperleptinemia, and 
TNF-α. Pediatr Res. 2013;73:388-394 (please see pages 29-35). 
 
B. Araújo JR, Correia-Branco A, Ramalho C, Gonçalves P, Pinho MJ, Keating E, Martel F. L-
methionine placental uptake: characterization and modulation in gestational diabetes 
mellitus. Reprod Sci. 2013;20:1492-1507 (please see pages 37-52). 
 
C. Araújo JR, Correia-Branco A, Ramalho C, Keating E, Martel F. Gestational diabetes mellitus 
decreases placental uptake of long-chain polyunsaturated fatty acids: involvement of long-
chain acyl-CoA synthetase. J Nutr Biochem. 2013;24:1741-1750 (please see pages 53-62). 
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It is currently accepted that GDM precipitates offspring’s risk for developing 
adverse perinatal outcomes and cardiometabolic [Boney et al., 2005; Gluckman et 
al., 2008] and neurological [Ornoy, 2005; Stenninger et al., 1998] complications 
later in life. However, the exact molecular mechanisms underlying this pathological 
and programming effects are still largely unexplored [Lehnen et al., 2013]. One 
hypothesis is that GDM affects the maternal-to-fetal transport of nutrients 
[Metzger et al., 2007] and placental development [Simeoni and Barker, 2009], 
thereby inducing lifelong changes in gene expression through epigenetic 
mechanisms. 
Nutrient transporters present in the STB epithelium have been suggested to 
play an important role in fetal programming because: 1) transporters activity and 
expression constitute an important determinant of fetal growth and development 
[Jansson et al., 2009]; 2) epigenetic modifications, in particular gene methylation, 
depend on an adequate provision of nutrients such as folates, L-Met [Jansson et al., 
2009], and LC-PUFAs [Kulkarni et al., 2011] (Fig. 2) and changes in placental 
transport of these nutrients will alter their availability to the fetus, providing a 
direct link between placental function, gene methylation and fetal programming; 
and 3) placental nutrient transporters may be themselves key targets for 
epigenetic modification [Jansson et al., 2009; Jansson and Powell, 2007]. 
So, considering the important role of nutrient transporters in determining 
fetal growth and future health of the newborn, the first aim of this work was to 
investigate if GDM (diagnosed according to [Carpenter and Coustan, 1982]) 
affected the placental transport of FA, L-Met and essential LC-PUFAs (AA and 
DHA). For that, we characterized the uptake of 3H-FA, 14C-L-Met, 14C-AA and 14C-
DHA by NTB cells and compared it with the uptake by DTB cells. 
Human primary cultured cytotrophoblasts are a suitable model to study the 
placental transport function because they spontaneously differentiate into a 
functional and polarized STB-like structure that retains all the cellular machinery 
of the in vivo STB [Bischof and Irminger-Finger, 2005; Bloxam et al., 1997; Kliman 
et al., 1986; Lager et al., 2011]. When comparing 3H-FA transport characteristics in 
NTB and DTB cells, we found that, although intracellular accumulation of 3H-FA 
was similar in both cells, DTB cells showed higher rates of inward and outward 
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transport, suggesting that in GDM placentas a higher turnover of intracellular FA 
was required to maintain FA homeostasis (publication A). 
Keating et al. reported that FA uptake by NTB cells is pH-dependent, 
operating optimally at acidic pH (5.0–5.5), and shows different transport 
characteristics at acidic (5.5) and physiological (7.5) pH [Keating et al., 2009a]. 
Similarly to the in vivo situation [Solanky et al., 2010], FA uptake into NTB cells at 
pH 7.5 was shown to involve RFC1, FR-α and PCFT [Keating et al., 2009a], 
reinforcing the suitability of this cell model to study FA placental transport. In 
addition, at pH 5.5, RFC1 and PCFT seem to mediate FA apical uptake into NTB 
cells [Keating et al., 2009a]. 
In the present work, we showed that 3H-FA uptake by both NTB and DTB 
cells exhibited similar kinetics and occurred optimally at an acidic pH. However, a 
greater pH-dependence was observed in DTB cells for low pH values (5.0–6.0), 
which could indicate a proportionally greater involvement of the high affinity 
folate:H+ symporter PCFT. In other words, there seemed to be a higher PCFT:RFC1 
relative activity in DTB in comparison with NTB cells (publication A). 
As a whole, these results suggested that, although quantitatively similar to 
normal pregnancies, placental transport of FA was more dependent on PCFT than 
on RFC1 in GDM pregnancies (publication A). Since GDM modulates the 
methylation of genes responsible for fetal growth and energy metabolism at 
placental level [Lehnen et al., 2013], and methylation of RFC1 gene is associated 
with a lower expression of this transporter [Farkas et al., 2013], we can speculate 
that GDM affects FA transport through epigenetic mechanisms. 
Comparison of the uptake of L-Met, another nutrient crucial for methylation 
reactions, between NTB and DTB cells, revealed that 14C-L-Met uptake was 
quantitatively similar in both cells, in a similar way as described for FA. 
Specifically, our results showed that 14C-L-Met uptake in both NTB and DTB cells 
presented a similar profile of time-dependence, kinetics and Na+-independence 
(publication B). Additionally, system L, more specifically its LAT1 isoform, 
seemed to greatly contribute (40-60%) to 14C-L-Met uptake in both NTB and DTB 
cells. System y+L (possibly corresponding to y+LAT2 activity) was also functionally 
present in both NTB and DTB cells, although it had a small contribution 
(approximately 20%) to 14C-L-Met uptake. On the other hand, some differences 
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were apparent: systems A and b0+ and LAT2 system L isoform were functionally 
capable of transporting L-Met in DTB cells only, and system y+L (possibly through 
the activity of both y+LAT1 and y+LAT2) seemed to be more active in DTB 
compared to NTB cells (publication B). 
We also investigated if the differences in the uptake characteristics of 14C-L-
Met uptake in NTB and DTB cells were associated with differences at the 
transcriptional level (mRNA) of amino acid transporters. The mRNA levels of 
SNAT1 and SNAT2 (the major system A isoforms present in STB during late 
gestation) [Tsitsiou et al., 2011]), and of LAT2 and y+LAT1 were similar in NTB and 
DTB cells (publication B). System b0+ expression was not tested because its 
function at the MVM and BM of the human STB is still under discussion [Ayuk et al., 
2000; Cleal et al., 2011; Cleal and Lewis, 2008; Jansson et al., 2002]. 
Data available on placental transport of amino acids in GDM pregnancies is 
conflicting: either an increase [Jansson et al., 2002] or no alteration [Dicke and 
Henderson, 1988; Nandakumaran et al., 2004] in systems A and L activity and no 
alterations in the transport of L-Lys (a substrate of systems y+ and y+L) [Jansson et 
al., 2002] have been described. The contrasting findings between these studies 
(including our own) may be the result of differences in study populations 
(different maternal body mass index, metabolic control following diagnosis, 
therapeutics of GDM, GDM diagnostic criteria, incidence of large-for-gestational-
age infants and fetal and placental weights). 
In conclusion, the results of L-Met uptake showed that GDM does not 
quantitatively alter L-Met placental transport capacity, although it involved 
distinct amino acid transporters (LAT1 and y+LAT2 in NTB cells and LAT1 and 2, 
y+LAT1 and 2 and systems A and b0,+ in DTB cells) (publication B). Given the 
broad substrate specificities of systems L, y+L, A and b0+ (see Introduction), we 
suggest that the transport of other neutral amino acids and of cationic amino acids 
may be altered in GDM pregnancies. Considering this, it will be important to study 
the placental transport of other amino acids in this disease. 
GDM adversely affects behavioral, cognitive and intellectual development of 
the offspring [Fraser et al., 2012; Larque et al., 2011; Ornoy, 2005] (see 
Introduction), and low LC-PUFAs concentrations (which are important for fetal 
neurological and visual development [Innis, 2005]) are observed in placentas 
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[Pagan et al., 2013] and cord blood [Min et al., 2005; Pagan et al., 2013; Thomas et 
al., 2005] obtained from GDM pregnancies, indicating that maternal-to-fetal 
transfer of LC-PUFAs might be impaired. According to this, it seemed of particular 
importance to compare placental transport of LC-PUFAs in normal and GDM 
pregnancies.  
Uptake of 14C-AA and 14C-DHA by NTB cells was shown to involve both a 
protein-mediated mechanism - which was quantitatively more important for lower 
substrate concentrations - and simple diffusion – which was quantitatively more 
important for higher substrate concentrations (publication C). This observation is 
in agreement with claims of other authors suggesting that under blood 
physiological concentrations of LC-PUFAs, most of the cellular uptake in peripheral 
tissues (eg. skeletal muscle, adipose tissue and heart) occurs via a protein-
mediated pathway, simple diffusion being quantitatively less important (reviewed 
by [Bonen et al., 2007; Doege and Stahl, 2006]). In a more detailed characterization 
of protein-mediated uptake of 14C-AA and 14C-DHA, we could demonstrate that this 
process greatly depended on the activity of ACSL, as it was markedly inhibited by 
triacsin C, a potent inhibitor of ACSL activity [Tobin et al., 2009; Tomoda et al., 
1991] (publication C). On the other hand, the ATP-independence of 14C-AA and 
14C-DHA uptake argued against the involvement of FATP in this process 
(publication C). So, we could conclude that ACSL-mediated fatty acid esterification 
into acyl-CoA was an important mediator of the placental transport of 14C-AA and 
14C-DHA (publication C). Nevertheless, because 14C-AA and 14C-DHA uptake by 
NTB cells was strongly (40-50%) though not completely inhibited by triacsin C, we 
cannot rule out the potential involvement of other transporters in this process, in 
particular pFABPpm (publication C), which has a preferential affinity for AA and 
DHA and is found exclusively on the MVM of the STB (please see Introduction). 
However, since pFABPpm protein and its gene sequence has not yet been 
described, further information on its structure and function is needed before more 
detailed conclusions can be drawn regarding its involvement in LC-PUFAs 
placental transport [Gil-Sanchez et al., 2012; Larque et al., 2011]. 
Uptake of both LC-PUFAs was found to be markedly reduced (≥ 50%) in 
DTB cells, through a decrease in both protein-mediated uptake and simple 
diffusion, suggesting a compensatory downregulation of fatty acid transporters at 
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the placental level in response to high nutritent availability, an hallmark of GDM. 
LC-PUFAs uptake downregulation was associated with a quantitatively similar 
reduction of ACSL1 mRNA levels in DTB cells (publication C). Both these 
observations supported the involvement of ACSL1 in the placental transport of 14C-
AA and 14C-DHA, and clearly indicated that the decrease in its expression 
underlined the decrease in 14C-AA and 14C-DHA uptake found in DTB cells. Also 
important is the fact that the interaction between FATP and ACSL, ie. matched 
activity and/or expression, which is still a matter of debate [Doege and Stahl, 2006; 
Richards et al., 2006], did not appear to exist in primary trophoblast cells, 
according to our results (publication C). 
By clearly showing a decrease in the placental uptake of LC-PUFAs associated 
with a decrease in ACSL1 gene expression in GDM, our results may well explain the 
reduced plasma levels of AA and DHA found in neonates born from women with 
GDM [Min et al., 2005; Pagan et al., 2013; Thomas et al., 2005; Wijendran et al., 
2000], and the neurodevelopmental fetal malprogramming associated with this 
disease [Pagan et al., 2013].  
Due to the crucial role that LC-PUFAs have for fetal visual, behavioral and 
cognitive development [Cunningham and McDermott, 2009; Duttaroy, 2009], 
further investigation is needed to elucidate if maternal LC-PUFAs supplementation 
during pregnancy, which has been proved in a clinical trial to increase fetal levels 
of LC-PUFAs [Carlson et al., 2013], can overcome GDM-induced adverse health 
outcomes in the newborn associated with an insufficient fetal supply of LC-PUFAs. 
 
Normal placental development relies on a balanced growth, proliferation, 
differentiation and programmed cell death of trophoblasts [Huppertz and Herrler, 
2005]. Alterations in these properties have been associated with miscarriage 
[Minas et al., 2007; Pestka et al., 2011], preeclampsia [Arnholdt et al., 1991; Shaker 
and Sadik, 2013] and FGR [Erel et al., 2001; Ishihara et al., 2002]. Since there is 
scarce and conflicting knowledge concerning the impact of GDM on these 
properties [Belkacemi et al., 2013; Sgarbosa et al., 2006], we decided to compare 
the viability, proliferation, differentiation and apoptosis of both NTB and DTB cells. 
A marked and similar increase in proliferation and apoptosis, but no change in 
viability or differentiation, was observed in DTB, in relation to NTB cells. These 
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observations suggested that a higher cell turnover may be present in DTB cells as a 
GDM-related phenotype (publication C). Sgarbosa and co-workers also reported 
an increase in trophoblast apoptosis in GDM, and suggested that hyperglycemia 
may be a key factor evoking this response [Sgarbosa et al., 2006]. On the other 
hand, Belkacemi et al. reported a decrease in trophoblast apoptosis with no change 
in proliferation in GDM placentas [Belkacemi et al., 2005]. These contrasting 
results, in comparison with ours, can be explained by differences in GDM therapy 
(women were treated with either diet or diet associated with metformin in 
Belkacemi’s study and in our study women were treated with diet or diet 
associated with insulin) and placental and neonatal birth weight (which were both 
higher in GDM compared with control women in Belkacemi’s study, but not in 
ours).  
Trophoblast development has been demonstrated to be regulated by GDM-
associated hallmarks. In extravillous trophoblasts, we observed that 
hyperinsulinemia increased proliferation and TNF-α increased viability, although 
hyperglycemia and hyperleptinemia did not affect these properties (Araújo et al. 
preliminary results) (publication C). In human villous trophoblasts, leptin 
stimulates proliferation and inhibits apoptosis [Gambino et al., 2012] and TNF-α 
induces apoptosis [Al-Nasiry et al., 2006; Yui et al., 1994] and proliferation [Yang 
et al., 1993]. Altogether, these observations suggest that GDM may impair placental 
development through many of the conditions associated with it. 
From the analysis and discussion of the results presented in chapter I we can 
conclude that GDM can disturb the maternal-to-fetal transport of nutrients, 
particularly of LC-PUFAs, and also trophoblast development. These alterations may 
eventually contribute to the fetal and postnatal adverse health outcomes 
associated with GDM. 
 
Oxidative stress is defined as an imbalance in pro-oxidants and antioxidants, in 
favor of the former [Jones, 2008]. Pregnancy per se is considered as a physiological 
state of oxidative stress [Chen and Scholl, 2005], which is important for embryo 
implantation, for fetal and placental development, and for labor [Myatt, 2010]. 
However, at abnormally high levels, oxidative stress can cause damage to 
macromolecules (inhibiting their normal function [Burton and Jauniaux, 2011]) 
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and disruption of intracellular signaling pathways [Jones, 2008], leading ultimately 
to cell death [Shaker and Sadik, 2013]. Oxidative stress has been implicated in the 
pathophysiology of prevalent pregnancy disorders, such as miscarriage [Myatt and 
Cui, 2004], preeclampsia [Siddiqui et al., 2010], FGR [Son et al., 2004; Takagi et al., 
2004] and maternal diabetes (T1D and GDM) [Lappas et al., 2011; Peuchant et al., 
2004; Toescu et al., 2004]. This condition has also been demonstrated to program 
the fetus to develop metabolic and cardiovascular complications later in life 
[Giussani et al., 2012; Thompson and Al-Hasan, 2012]. 
In both T1D and GDM, increased levels of oxidative stress have been found in 
maternal plasma and serum [Peuchant et al., 2004; Rajdl et al., 2005; Toescu et al., 
2004], but the placenta have been scarcely studied [Pustovrh et al., 2000]. Due to 
this, we decided to compare the oxidative stress levels and antioxidant capacity in 
placentas from GDM, T1D and control women. 
From the analysis of our results, we could observe that two widely accepted 
biomarkers of oxidative damage (malonaldehyde [MDA] and protein carbonyls) 
[Dalle-Donne et al., 2006] were elevated in T1D, but not in GDM placentas, when 
compared to controls (publication D). 
Antioxidants are compounds of enzymatic or non-enzymatic origin that inhibit 
or delay the production of ROS and the consequent oxidation of biomolecules [Al-
Gubory et al., 2010]. Glutathione, the major cellular non-enzymatic antioxidant [Al-
Gubory et al., 2010] and the antioxidant enzyme glutathione peroxidase (GPx) 
[Agarwal et al., 2012] are reliable indicators of antioxidant status [Chen and Scholl, 
2005]. When compared to control and GDM placentas, higher reduced (GSH) and 
lower oxidized (GSSG) glutathione concentrations were found in T1D placentas. On 
the other hand, GSX, GSH and GSSG levels were similar in GDM and control 
placentas (publication D). Additionally, GPx activity was higher in T1D but not in 
GDM placentas, in comparison to control ones. These results suggest that a 
compensatory antioxidant mechanism may develop in T1D placentas to overcome 
higher oxidative stress levels. In agreement with our results, a parallel increase in 
blood levels of oxidative stress biomarkers and antioxidant enzymes activity have 
been reported in T1D pregnant women [Al-Shebly and Mansour, 2012; Orhan et al., 
2003]. On the other hand, we found that placental oxidative stress and 
antioxidants levels were unaltered in GDM, even after stratification for GDM 
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therapy, mode of delivery and large-for-gestational age newborns (publication D). 
This observation is in contrast to previous studies that associated GDM with 
increased levels of oxidative stress [Biri et al., 2006; Coughlan et al., 2004; Gelisgen 
et al., 2011; Toescu et al., 2004]. We believe that the main reason for this apparent 
inconsistency is that women in our GDM group were diagnosed according to the 
new IADPSG criteria [Long and Cundy, 2013; Metzger et al., 2010], which 
encompassed women with a less severe diabetic phenotype. Of note, our GDM 
women showed third trimester fasting glycemia that is not characteristic of overt 
diabetes (≤ 5.0 mM) [ADA, 2013; Anger et al., 2012] and glycosylated hemoglobin 
levels at term that were within the acceptable range for managed diabetes (≤ 5.7 
%). In contrast, maternal third trimester fasting glycemia in T1D women was 
characteristic of overt diabetes (7.9 mM), which was positively correlated with 
placental MDA levels (publication D). 
As a whole, the results from chapter II: 1)  showed that T1D, but not GDM, is 
associated with increased oxidative stress at the placental level; 2) support the 
concern that the new IADPSG criteria may be diagnosing as GDM a large number of 
women that may not in fact be metabolically at high risk [ADA, 2013; Long and 
Cundy, 2013], with consequences in terms of maternal stress, quality of life and of 
health care costs [Long and Cundy, 2013]; and 3) support the role of 
hyperglycemia as an important condition associated with increased oxidative 
stress in T1D pregnancies [Chen and Scholl, 2005; Lappas et al., 2011; Peuchant et 
al., 2004].  
Altought we did not found increased levels of oxidative stress at placental level 
in GDM, this condition has been reported to be present in blood of GDM women 
(see above). Also, increased levels of oxidative stress have been found in placentas 
obtained from pregnancies complicated by FGR [Karowicz-Bilinska et al., 2004] 
and preeclampsia [Gulmezoglu et al., 1996; Zusterzeel et al., 2001]. According to 
this, and considering that glucose is the primary substrate for fetal oxidative 
metabolism [Hahn et al., 1999], it seemed particularly interesting to investigate if 
oxidative stress altered the placental transport of glucose (chapter III, 
publication E). To accomplish this, we first characterized the uptake of 3H-2-
deoxy-D-glucose (3H-DG) – a D-glucose analogue efficiently transported by GLUT 
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transporters [Shah et al., 1999] - by the human choriocarcinoma-derived cell line 
BeWo (publication E). 
BeWo cells are a well-characterized trophoblast cell model that is widely used 
to study placental transport of nutrients [Bode et al., 2006; Sastry, 1999]. They 
show great stability, life-span and viability with passage, easy maintenance and 
absence of patient variability [Antony et al., 2007; Bode et al., 2006]. Additionally, 
BeWo cells grow rapidly and form a confluent and polarized monolayer that 
exhibit morphological, hormonal and enzymatic properties common to NTB cells 
[Bode et al., 2006; Liu et al., 1997]. 
Our results indicated that 3H-DG uptake by BeWo cells mainly involved a Na+-
independent, insulin-insensitive and low affinity (Km = 13.4 mM), high capacity 
(Vmax = 1210 nmol mg protein−1 6 min−1) transporter, that most probably 
corresponded to GLUT1 (publication E), which is the most functional glucose 
carrier present in the human STB [Baumann et al., 2002] (please see Introduction, 
section 2.2.4.).  
To investigate the effect of oxidative stress upon the transport of glucose, 
BeWo cells were exposed to tert-butylhydroperoxide (TBHP) for 24h, which 
increased the intracellular levels of oxidative stress biomarkers (MDA, carbonyl 
groups and GSSG) without compromising cellular viability (publication F). Similar 
oxidative modifications have been found in blood of GDM women [Biri et al., 2006; 
Coughlan et al., 2004; Gelisgen et al., 2011; Toescu et al., 2004]. 
TBHP-induced oxidative stress reduced GLUT-mediated placental 
accumulation of 3H-DG. This effect was not associated with changes in either 
GLUT1 mRNA levels or intracellular glucose metabolism (glycolysis). Moreover, it 
was associated with an increase in 3H-DG paracellular and hence transepithelial 
transport (publication F). Paracellular transport of glucose, although poorly 
defined, has been recently demonstrated to occur across the human STB [Day et al., 
2013]. 
The intracellular signaling pathways PI3K and PKC, known to regulate 
placental glucose transport [Lappas et al., 2012; Riley et al., 2005], did not seem to 
be involved in the inhibitory effect of oxidative stress upon 3H-DG accumulation 
(publication F). Interestingly, Lappas and co-workers, although using a different 
oxidative challenge (hypoxanthine and xanthine oxidase) and placental model 
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(explants), also reported that nuclear factor kappa B and PI3K signaling pathways 
were not involved in the inhibitory effect of oxidative stress upon GLUT1-mediated 
transport [Lappas et al., 2012]. 
In experimental diabetic pregnancy, maternal supplementation with dietary 
antioxidants has been shown to reduce maternal oxidative stress and improve fetal 
health outcomes [Cederberg and Eriksson, 2005; Cederberg et al., 2001; Siman and 
Eriksson, 1997]. So, we decided to investigate if antioxidants were able to reverse 
the inhibitory effect of oxidative stress upon 3H-DG accumulation in BeWo cells. 
The dietary polyphenolic compounds quercetin, epigallocatechin-3-gallate 
(EGCG) and resveratrol totally abolished the reduction in 3H-DG accumulation 
induced by oxidative stress, by specifically reversing the effect of TBHP upon 
GLUT-mediated transport (publication F). Interestingly, quercetin, EGCG and 
resveratrol have been previously found to prevent the inhibitory effect of oxidative 
stress upon the transport of other nutrients, more specifically folic acid [Couto et 
al., 2012], butyrate [Gonçalves et al., 2013] and glucose [Lappas et al., 2012]. Their 
effect was associated with a decrease in lipid peroxidation [Gonçalves et al., 2013] 
and with an increase in the expression of antioxidant responsive genes [Lappas et 
al., 2012]. 
Also in this work, the ROS scavengers N-acetyl-L-cysteine and α-tocopherol 
(the most active form of vitamin E) and inhibitors of ROS-generating enzymes 
(NADPH and xanthine oxidase) did not reverse the inhibitory effect of oxidative 
stress upon 3H-DG accumulation, suggesting that this effect did not depend upon 
ROS generation (publication F). This can be explained by the fact that, for 
endogenous antioxidants such as vitamin E and glutathione (for which N-acetyl-L-
cysteine is a precursor [Gallo et al., 2010]), the interaction of multiple systems is 
necessary to counteract oxidative processes. For instance, the antioxidant activity 
of vitamin E needs to be supported by the activity of GSH and vitamin C [Gallo et 
al., 2010]. 
 
GDM is associated with elevated maternal blood levels of glucose, insulin, 
leptin, inflammatory mediators and oxidative stress (see Introduction). The 
placenta, mainly the STB, may contribute for the appearance of these conditions 
since it produces a large number of proinflammatory cytokines (eg. TNF-α and IL-
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6), hormones (eg. leptin) [Desoye and Hauguel-de Mouzon, 2007; Jansson et al., 
2009] and ROS [Myatt and Cui, 2004] that can be released into both the maternal 
and fetal circulations. 
The results presented in chapter III (publications A, B, C and G) identified 
which specific GDM molecular hallmarks interfered with the placental transport of 
FA, amino acids and LC-PUFAs. In this context, the effect of GDM-associated 
conditions - increased levels of glucose, insulin, leptin, proinflammatory mediators 
(lipopolysaccharide [LPS] and TNF-α) and oxidative stress - upon the uptake of  3H-
FA, 14C-L-neutral amino acids (14C-L-Met and 14C-L-Alanine [14C-L-Ala]) and 14C-LC-
PUFAs by NTB or BeWo cells were investigated. Additionally, the uptake of 14C-L-
Met was also characterized in BeWo cells. 
The characteristics of FA transport were previously shown to be very similar 
in both NTB and BeWo cells [Keating et al., 2007; Keating et al., 2006; Keating and 
Martel], reinforcing the suitability of both cell models to study the placental 
transport of FA. Concerning the characterization of 14C-L-Met uptake in BeWo cells, 
we found it to be similar to uptake by NTB cells. Both processes showed similar 
time-dependence and kinetics (with an affinity in the micromolar range) and were 
mainly Na+-independent and system L (more specifically LAT1 isoform)-mediated, 
(publication B). Although system L was the major transporter responsible for 14C-
L-Met uptake in BeWo cells (± 50%) it did not account for the entire uptake. So, a 
non-system L-mediated transporter also appeared to participate in this process, 
which most probably corresponds to system y+. In fact, besides transporting 
cationic amino acids (eg. L-Lys and L-arginine), system y+ has also been 
demonstrated to be involved in the transport of large neutral amino acids 
[Battaglia and Regnault, 2001; Jansson et al., 2001; Martin-Venegas et al., 2009]. At 
least 3 isoforms of system y+ are expressed in the human STB: CAT1, CAT2B and 
CAT4 [Carter, 2012].  
The involvement of system y+ in 14C-L-Met by Bewo cells was strongly 
suggested by the N-ethylmaleimide (NEM) and L-Lys-sensitivity of non-system L-
mediated uptake (NEM and L-Lys are inhibitors of system y+-mediated transport 
[Deves et al., 1993]) and by the similar affinity of non-system L-mediated uptake 
(Km ± 142 μM) with that of CAT1- and CAT2B-mediated uptake (Km ± 100–400 μM) 
[Casanello et al., 2009; Sobrevia and Gonzalez, 2009] (publication G). 
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To study the effect of GDM-associated conditions upon 3H-FA, 14C-L-Met, 14C-
AA and 14C-DHA placental uptake, BeWo or NTB cells were short- (26 min - 4h) or 
long-term (24-72h) exposed to those conditions.  
Our results showed that short (4h) and particularly long-term (24h) 
hyperleptinemia decreased 3H-FA uptake, and that short-term (4h) exposure to 
LPS (in concentrations [1-10 μg/ml] known to induce IL-6 and TNF-α secretion by 
trophoblasts [Torricelli et al., 2009]) or to high levels of TNF-α (300 ng/l) itself 
reduced 3H-FA uptake in BeWo cells. On the other hand, hyperglycemia and 
hyperinsulinemia were devoid of effect upon 3H-FA uptake (publication A). 
Leptin has important placental functions including regulation of nutrient 
metabolism and trophoblast proliferation, invasion and angiogenesis [Mouzaki et 
al., 2012; von Versen-Hoynck et al., 2009; White et al., 2004], suggesting that this 
hormone may affect fetal growth [D'Ippolito et al., 2012]. The functions attributed 
to leptin depend upon its binding to specific receptors, which have been localized 
in the human STB [von Versen-Hoynck et al., 2009], resulting in activation of the 
following signal transduction pathways: JAK (janus kinases)/STAT (signal 
transducers and activators of transcription), PI3K, protein kinases (PK) A and C, 
and mitogen-activated protein kinases (MAPK) such as extracellular-signal-
regulated-kinase (ERK), c-Jun-N-terminal kinase (JNK) and p38 MAPK [Fruhbeck, 
2006; von Versen-Hoynck et al., 2009]. However, further experiments searching 
for the intracellular pathways involved in the inhibitory effect of long-term leptin 
upon 3H-FA uptake in BeWo cells, showed that this effect seemed to be 
independent of JAK/STAT, PI3K, PKA, PKC and MAPK signaling pathways 
(publication A). 
Concerning the effect of GDM conditions upon the uptake of the neutral amino 
acids 14C-L-Met and 14C-L-Ala in BeWo cells, we observed that: a) oxidative stress 
(TBHP; 24h) reduced the uptake of 14C-L-Ala mediated by system A (publication 
G), and b) long-term hyperleptinemia, hyperglycemia (48-72h) and oxidative 
stress (TBHP; 24h) decreased, and hyperinsulinemia and high levels of LPS (1-50 
μg/ml) and TNF- (100-1000 ng/l) did not substantially alter, 14C-L-Met uptake 
(publications B and G). Further experiments aimed at characterizing the 
inhibitory effect of hyperleptinemia, hyperglycemia and oxidative stress upon 14C-
L-Met and 14C-L-Ala uptake revealed that: a) hyperglycemia and hyperleptinemia 
DISCUSSION AND CONCLUSIONS  
111 
 
appeared to inhibit system L-mediated 14C-L-Met uptake, whereas oxidative stress 
appeared to inhibit system y+-mediated 14C-L-Met uptake (publication B and G); 
b) the effect of hyperglycemia upon 14C-L-Met uptake seemed to be mTOR-
independent, whereas the effect of hyperleptinemia upon 14C-L-Met uptake 
seemed to be PI3K-, ERK- and p38 MAPK-dependent (publication B); and c) the 
inhibitory effect of oxidative stress upon 14C-L-Ala uptake seemed to be PI3K- and 
PKC-dependent and was completely prevented by the polyphenolic compound 
quercetin (publication G). 
Maternal intake of quercetin, one of the most abundant polyphenols found in 
the human diet [Aherne and O'Brien, 2002], during gestation has been reported to 
decrease DNA oxidation in offspring tissues, thereby decreasing their susceptibility 
to develop oxidative stress-related diseases latter in life [Vanhees et al., 2013]. So, 
we suggest that the protective role of quercetin against oxidative stress-induced 
inhibition of L-Ala placental transport, observed by us, is probably related with its 
antioxidant capacity (publication G). 
We also studied the modulation of placental uptake of 14C-AA and 14C-DHA by 
GDM-associated conditions (publication C). Our results showed that, in NTB cells, 
short-term (26 min) exposure to high levels of TNF-α (100 ng/l) increased both 
14C-AA and 14C-DHA uptake, whereas short-term hyperinsulinemia increased 14C-
DHA uptake. Hyperglycemia and hyperleptinemia were devoid of effect upon 14C-
AA and 14C-DHA uptake (publication C). 
Nuclear receptors such as peroxisome proliferator-activated receptors, 
retinoid X receptors and liver X receptors (LXR) are key regulators of placental 
fatty acids transport and metabolism [Duttaroy, 2009]. Since activation of LXR has 
been shown to increase ACSL-mediated transport of LC-PUFAs in human 
trophoblast [Weedon-Fekjaer et al., 2010] and inducers of proinflammatory 
cytokines production (such as TNF-α) [Aye et al., 2012] and insulin [Chen et al., 
2004] were shown to activate LXR, we suggest that the effect of hyperinsulinemia 
and of high levels of TNF-α upon 14C-AA and 14C-DHA in NTB cells uptake may 
depend on LXR activation. 
Altogether, the results from chapter III suggest that GDM-associated 
conditions, in particular hyperleptinemia, high inflammatory status and oxidative 
stress, may act as regulators of placental nutrient transport and thus of fetal 
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growth. On the other hand, both hyperglycemia and hyperinsulinemia do not seem 
to have a great impact upon the placental transport of nutrients. These results are 
particularly interesting considering that leptin [Bouret et al., 2004; Mouzaki et al., 
2012], proinflammatory mediators [Mouzaki et al., 2012] and oxidative stress 
[Giussani et al., 2012; Thompson and Al-Hasan, 2012] have been reported to be 
important players in fetal programming.  
An additional point to discuss is the contrasting effect of some GDM-associated 
conditions upon the transport of L-Met, FA and LC-PUFAs (chapter III) and the 
transport of these nutrients in DTB in comparison with NTB cells (chapter I) 
(Table 1). This observation implies that the effect of GDM upon the placental 
transport of nutrients cannot be attributed to a single GDM condition, but rather to 
a complex interaction between multiple conditions. 
 
Placental uptake of nutrients
Folic acid L-Met L-Ala DHA AA Glucose
Hyperglycemia =  = =
Hyperinsulinemia = =  =
Hyperleptinemia   = =
Inflammation (TNF-α)  =  
Inflammation (LPS)  = = =
Oxidative Stress   = = 
GDM = =  
AA: arachidonic acid; DHA: docosahexaenoic acid; FA: folic acid; L-Met: L-methionine; L-Ala: L-Alanine; : decrease in
uptake;: increase in uptake; =: uptake not altered.
Table 1. Effect of gestational diabetes (GDM) and its associated conditions upon the placental
uptake of nutrients
 
 
As a general conclusion of this study, we can say that GDM induces alterations 
in placental development and transport of nutrients which may ultimately 
contribute to the fetal and postnatal adverse health outcomes associated with 
GDM. Because these nutrients are involved in the metabolism of methyl groups 
necessary for epigenetic regulation, we can speculate that these alterations may 
eventually contribute for the fetal programming effects associated with this 
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disease, suggesting a close link between GDM, placental function and fetal 
programming. 
 
The final conclusions of this study are listed below. 
 
With respect to the placental transport of nutrients in normal and GDM 
pregnancies: 
 
1) Folic acid (FA) transport in human cytotrophoblasts isolated from normal 
and GDM pregnancies (NTB and DTB cells, respectively) was quantitatively 
similar, although in DTB cells it depended more on the activity of PCFT 
 
2) L-methionine (L-Met) transport by NTB and DTB cells was mainly mediated 
by system L 
 
3) In NTB and DTB cells, L-Met transport was quantitatively similar although it 
involved the interplay of different transporters: system L was involved in L-
Met transport in NTB and DTB cells, but LAT2 and systems A and b0+ were 
capable of transporting L-Met only in DTB cells, and system y+L seemed to be 
more active in DTB compared with NTB cells 
 
4) LC-PUFAs transport by NTB cells involved both a protein-mediated 
mechanism (dependent upon long-chain acyl-CoA synthetases - ACSL) and 
simple diffusion 
 
5) Transport capacity of LC-PUFAs was markedly reduced in DTB cells, which 
was coincident with a reduction of similar magnitude in ACSL1 gene 
expression 
 
With respect to placental development in normal and GDM pregnancies: 
 
6) DTB cells seemed to have a higher cell turnover when compared to NTB 
cells 
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With respect to assessment of GDM-associated hallmarks and their effect 
upon placental nutrient transport: 
 
7) Higher levels of oxidative stress along with an increased antioxidant 
capacity were present in T1D placentas, compared to normal and GDM 
placentas. Oxidative stress and antioxidants levels were unaltered in GDM 
placentas 
 
8) Oxidative stress (induced by tert-butylhydroperoxide) reduced GLUT-
mediated 3H-2-D-deoxyglucose (3H-DG) cellular accumulation, but stimulated 
its paracellular transport  
 
9) Hyperleptinemia and high levels of LPS and TNF-α per se decreased FA 
uptake in a human trophoblast cell line (BeWo cells) 
 
10) Hyperleptinemia and hyperglycemia per se decreased system L-mediated 
L-Met uptake in BeWo cells 
 
11) Oxidative stress (induced by tert-butylhydroperoxide) reduced non-
system L-mediated uptake of L-Met (probably via system y+), and system A-
mediated L-Ala uptake in BeWo cells 
 
12) In NTB cells, high levels of TNF-α increased both AA and DHA uptake, 
whereas hyperinsulinemia increased only DHA uptake 
 
Several physiological implications arise from these main conclusions:  
 
1) In GDM pregnancies, the reduced placental uptake of LC-PUFAs and 
decreased ACSL1 gene expression, originating an insufficient supply of AA and 
DHA to the placenta and fetus, may constitute one possible mechanism underlying 
GDM fetal programming of neurological disorders 
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2) Alterations in fetal growth associated with GDM might not be explained by 
quantitative changes in placental transport of FA and L-Met 
 
3) The known regulatory effect of GDM upon the placental transport of 
nutrients cannot not be attributed to an isolated GDM-associated condition, but 
rather to the interplay of multiple conditions 
 
4) The observed increase in trophoblast proliferation and apoptosis may 
disturb the normal development of the placenta in GDM, and so ultimately induce 
perinatal and latter in life adverse health outcomes for both the mother and fetus  
 
5) The actual GDM diagnosis, based on the new IADPSG criteria, is likely to be 
diagnosing with GDM, women that may not really show relevant dysglycemia or 
oxidative imbalance 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FUTURE PERSPECTIVES 
 
  
 
 
 
 
 
 
 
FUTURE PERSPECTIVES  
119 
 
We believe that this work contributed for a better knowledge on the impact of 
GDM upon the placental transport of nutrients and placental development. 
However, it also showed that new aspects should be investigated in more detail, 
namely: 
a) the modulation of placental transport of cationic (eg. L-arginine) and neutral 
(eg. L-serine and L-histidine) amino acids by GDM and its associated conditions. 
These amino acids are substrates of LAT2 and y+LAT1 transporters and of systems 
A, y+ and b0,+ [Cleal and Lewis, 2008], which are altered in GDM, 
b) the effect of GDM-associated conditions upon the invasive, angiogenic and 
migration capacities of extravillous trophoblasts,  
c) the search for epigenetic modifications (DNA methylation) in placental FA, L-
Met and LC-PUFAs transporter genes in GDM 
d) the impact of maternal AA and DHA supplementation during the 
perigestational period (which extends from conception throughout pregnancy till 
the end of lactation) in the metabolic and neurologic phenotype of offsprings born 
from GDM women.  
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Gestational diabetes mellitus (GDM) is the most prevalent metabolic 
disorder diagnosed in pregnant women. This disease increases the risk of adverse 
perinatal outcomes and later in life metabolic and neurological diseases for the 
newborn. However, the cellular and molecular mechanisms underlying these 
pathological and programming effects of GDM are still largely unexplored.  
The human placenta is the main interface between the maternal and fetal 
blood circulations, being responsible - at the level of the syncytiotrophoblast 
epithelium - for the maternal-to-fetal transfer of nutrients essential for fetal 
growth and development. In this context, we hypothesized that changes in 
placental transport function and development may be present in GDM pregnancies. 
So, our main aim was to investigate the effect of GDM and its associated 
hallmarks (hyperglycemia, hyperinsulinemia, hyperleptinemia and elevated levels 
of inflammation and oxidative stress) upon the placental transport of folic acid 
(FA), neutral amino acids (L-methionine [L-Met] and L-alanine [L-Ala]), long-chain 
polyunsaturated fatty acids (arachidonic [AA] and docosahexaenoic [DHA] acids) 
and glucose, and upon placental development. Additionaly, we also aimed to assess 
oxidative stress status in GDM placentas. 
Our results led us to conclude that: a) FA and L-Met uptake by human 
trophoblasts isolated from both normal and GDM pregnancies (NTB and DTB cells, 
respectively) was quantitatively similar, although it involved the interplay of 
distinct transporters; b) AA and DHA uptake (which was both mediated by simple 
diffusion and by transporter proteins) was markedly reduced in DTB cells, 
coincident with a similar reduction of long-chain acyl-CoA synthetase (ACSL) 1 
gene expression; and c) proliferation and apoptosis was higher in DTB than in NTB 
cells, suggesting a higher cell turnover.  
With respect to GDM-associated conditions, we verified that: a) in a human 
trophoblast cell line (BeWo cells) cells, hyperleptinemia and high levels of the 
inflammatory mediators lipopolysaccharide and tumor necrosis factor-alpha (TNF-
α) decreased FA uptake, and hyperleptinemia and hyperglycemia decreased 
system L-mediated L-Met uptake; b) in NTB cells high levels of TNF-α increased 
both AA and DHA uptake and hyperinsulinemia increased DHA uptake; c) placental 
oxidative stress and antioxidant levels were found to be increased in type 1 
diabetic pregnant women but unaltered in GDM women; and d) oxidative stress 
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(induced by tert-butylhydroperoxide) reduced the uptake of L-Met, most probably 
mediated by system y+, reduced system A-mediated uptake of L-Ala, and reduced 
facilitative glucose transporters (GLUT)-mediated 2-D-deoxyglucose (DG) uptake.  
In conclusion, GDM disturbs placental transport, and consequently fetal 
supply, of nutrients and it also alters trophoblast development. These effects 
eventually contribute to the fetal and post-natal adverse health outcomes 
associated with GDM.  
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A diabetes mellitus gestacional (DMG) é a doença metabólica mais comum 
diagnosticada em mulheres grávidas. Esta doença aumenta o risco de morbilidade 
perinatal bem como de doenças metabólicas e neurológicas a longo prazo no 
recém-nascido. Contudo, os mecanismos moleculares e celulares responsáveis por 
este efeito patológico e programador da DMG estão ainda muito pouco explorados. 
A placenta humana constitui a principal ligação entre a mãe e o feto, sendo 
responsável – ao nível do epitélio do sincíciotrofoblasto – pelo transporte 
materno-fetal de nutrientes necessários ao crescimento e ao desenvolvimento do 
feto. Neste contexto, levantamos a hipótese de que a DMG induz alterações na 
função transportadora e no desenvolvimento da placenta. 
Como tal, o nosso principal objetivo foi investigar o efeito da DMG e das 
condições a ela associadas (hiperglicemia, hiperinsulinemia, hiperleptinemia e 
níveis elevados de inflamação e stresse oxidativo) sobre o transporte placentário 
de ácido fólico (AF), aminoácidos (L-metionina [L-Met] e L-alanina [L-Ala]), ácidos 
gordos polinsaturados de cadeia longa (ácido araquidónico [AA] e 
docosahexaenóico [ADH]) e glicose, bem como sobre o desenvolvimento da 
placenta. Adicionalmente, foi também nosso objetivo avaliar o estado redox 
placentário na DMG.  
Os nossos resultados levaram-nos a concluir que: a) a captação de AF e L-
Met em trofoblastos humanos provenientes de gravidezes normais e com diabetes 
gestacional (células NTB e DTB, respetivamente) foi quantitativamente 
semelhante, apesar de estarem envolvidos mecanismos de transporte distintos; b) 
a captação de AA e ADH (que envolveu difusão simples mas também proteínas 
transportadoras) é marcadamente inferior nas células DTB, sendo acompanhado 
por uma redução da mesma ordem de grandeza da expressão génica da sintétase 
de acil-CoA de cadeia longa (ACSL) 1; e c) a proliferação e apoptose foi maior nas 
células DTB comparativamente às NTB, sugerindo uma maior velocidade 
renovação celular nas primeiras.  
Relativamente às condições da DMG, verificamos que: a) numa linha celular 
de trofoblastos humanos (células BeWo) a hiperleptinemia e níveis elevados dos 
mediadores inflamatórios lipopolissacarídeo e fator de necrose tumoral-alfa (TNF-
α) reduziram a captação de AF, e a hiperleptinemia e a hiperglicemia reduziram a 
captação de L-Met mediada pelo sistema L; b) em células NTB, níveis elevados de 
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TNF-α aumentaram a captação de AA e ADH e a hiperinsulinemia aumentou a 
captação de ADH, c) os níveis de stresse oxidativo e defesas antioxidantes estavam 
aumentados nas placentas provenientes de mulheres grávidas com diabetes tipo 1, 
mas não estavam alterados nas placentas provenientes de mulheres diabéticas 
gestacionais, e d) o stresse oxidativo (induzido pelo tert-butilhidroperóxido) 
reduziu a captação de L-Met mediada pelo sistema y+, a de L-Ala mediado pelo 
sistema A, e a de 2-D-desoxiglicose (DG) mediada pelos transportadores 
facilitativos de glicose (GLUT). 
Em conclusão, a DMG altera o transporte placentário, e consequentemente a 
disponibilidade fetal, de nutrientes bem como o desenvolvimento dos trofoblastos. 
Estas alterações podem eventualmente contribuir para os efeitos adversos da DMG 
sobre o feto e sobre o recém-nascido.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
